Next Article in Journal
Dermoscopic Features of Lichen Amyloidosis in Caucasians—A Case Series and Literature Review
Previous Article in Journal
IL-6 597A/G (rs1800797) and 174G/C (rs1800795) Gene Polymorphisms in the Development of Cervical Cancer in Lithuanian Women
Article

Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience

by 1,2, 1,2, 3,4,*, 1,2, 5, 1,2, 6 and 1,2
1
Department of Internal Medicine, Hematology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
2
Hematology Clinic, Timisoara’s Emergency City Hospital, 300723 Timisoara, Romania
3
Second Department of Internal Medicine, Diabetes, Nutrition, Metabolic Diseases and Systemic Rheumatology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
4
3rd Medical Clinic, Pius Brinzeu Emergency Hospital, 300041 Timisoara, Romania
5
Department of Neurology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
6
Department of Internal Medicine, Clinical Practical Skills, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Academic Editor: Mauro Salvatore Alessandro Alaibac
Medicina 2021, 57(10), 1026; https://doi.org/10.3390/medicina57101026
Received: 26 July 2021 / Revised: 17 September 2021 / Accepted: 22 September 2021 / Published: 27 September 2021
Background and objectives: Hodgkin lymphoma (HL) is characterized by the presence of malignant Reed Sternberg cells. Although the current curability rate in patients with HL has increased, up to 30% of those in the advanced stages and 5% to 10% of those in limited stages of the disease, relapse. According to the studies, the relapse risk in HL decreases after 2 years. The purpose of this study is to evaluate the relapse risk and event free survival (EFS) in patients with HL treated with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (ABVD), or treated with Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) regimens. Material and methods: In an observational, consecutive-case scenario, 71 patients (median age 32 years; range 16 to 80 years) diagnosed within a 4-year timeframe were enrolled; all patients were treated according to standards of care. The average follow-up duration was 26 months. Results: The risk of relapse, in patients older than 40 years, decreased after 1 year, OR = 0.707 (95% CI 0.506 to 0.988), and 2 years, OR = 0.771 (95% CI 0.459 to 1.295), respectively. Patients in the advanced stages had a higher International Prognostic Score (IPS) (score ≥ 4). The overall survival at 2 years was 57.74% and the disease-specific survival at 2 years was 71.83%. Regardless, the chemotherapy regimen and the EFS time, advanced stage, high IPS and bulky disease were still associated with an increased relapse risk in patients with HL. Conclusions: The use of ABVD chemotherapy regimen followed by 2 years EFS was associated with a reduced relapse risk. View Full-Text
Keywords: Hodgkin lymphoma; relapse risk; ABVD; BEACOPP; event free survival Hodgkin lymphoma; relapse risk; ABVD; BEACOPP; event free survival
MDPI and ACS Style

Potre, O.; Pescaru, M.; Sima, A.; Ionita, I.; Tudor, R.; Borsi, E.; Samfireag, M.; Potre, C. Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience. Medicina 2021, 57, 1026. https://doi.org/10.3390/medicina57101026

AMA Style

Potre O, Pescaru M, Sima A, Ionita I, Tudor R, Borsi E, Samfireag M, Potre C. Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience. Medicina. 2021; 57(10):1026. https://doi.org/10.3390/medicina57101026

Chicago/Turabian Style

Potre, Ovidiu, Monica Pescaru, Alexandra Sima, Ioana Ionita, Raluca Tudor, Ema Borsi, Miruna Samfireag, and Cristina Potre. 2021. "Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience" Medicina 57, no. 10: 1026. https://doi.org/10.3390/medicina57101026

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop